Vitamin d ergocalciferol
Pro Research Analysisby 
Searched over 200M research papers
Ergocalciferol (Vitamin D2) Supplementation: Efficacy and Clinical Implications
Introduction to Ergocalciferol and Vitamin D Deficiency
Ergocalciferol, also known as vitamin D2, is one of the two primary forms of vitamin D used in supplementation, the other being cholecalciferol (vitamin D3). Vitamin D deficiency is a widespread issue that can lead to various health problems, including bone disorders, cardiovascular diseases, and impaired immune function. This article synthesizes recent research on the efficacy of ergocalciferol supplementation in different populations and its comparison with cholecalciferol.
Ergocalciferol in Hemodialysis Patients
A randomized clinical trial investigated the effects of ergocalciferol supplementation in hemodialysis patients with vitamin D deficiency. The study found that while ergocalciferol significantly increased serum 25-hydroxyvitamin D (25(OH)D) levels, it did not affect epoetin utilization or other secondary biochemical and clinical outcomes such as serum calcium, phosphorus, and parathyroid hormone levels . This suggests that while ergocalciferol can correct vitamin D deficiency, it may not have broader clinical benefits in this patient group.
Comparative Efficacy of Ergocalciferol and Cholecalciferol
Several studies have compared the efficacy of ergocalciferol and cholecalciferol in raising serum 25(OH)D levels. Research consistently shows that cholecalciferol is more potent than ergocalciferol. For instance, a study in elderly women found that cholecalciferol increased serum 25(OH)D levels more effectively than ergocalciferol, regardless of the administration route . Another study in hip fracture patients also demonstrated that cholecalciferol was more effective in increasing serum 25(OH)D levels compared to ergocalciferol, although both forms had similar effects on parathyroid hormone (PTH) levels 67.
Ergocalciferol in Chronic Kidney Disease (CKD)
In children with CKD stages 2-4, ergocalciferol supplementation delayed the onset of secondary hyperparathyroidism, a common complication in CKD patients. The study showed that ergocalciferol effectively maintained normal 25(OH)D levels in most children with CKD stages 2-3, thereby delaying hyperparathyroidism . Another study in CKD patients found that ergocalciferol improved microcirculatory endothelial function, which may reduce cardiovascular risk in this population .
High-Dose Ergocalciferol in Postmenopausal Women
A study on institutionalized postmenopausal women compared the efficacy of high-dose (100,000 IU/week) versus standard-dose (40,000 IU/week) ergocalciferol. The high-dose group achieved more optimal 25(OH)D levels without significant differences in muscle strength, mobility, or quality of life compared to the standard-dose group . This suggests that higher doses of ergocalciferol may be more effective in correcting severe vitamin D deficiency.
Meta-Analysis and Systematic Review Findings
A systematic review and meta-analysis concluded that cholecalciferol is generally more effective than ergocalciferol in improving vitamin D status and regulating PTH levels across various demographics and dosages . This reinforces the notion that cholecalciferol should be preferred for vitamin D supplementation, especially in cases requiring significant increases in serum 25(OH)D levels.
Conclusion
While ergocalciferol is effective in raising serum 25(OH)D levels, it is generally less potent than cholecalciferol. In specific populations, such as children with CKD and institutionalized postmenopausal women, ergocalciferol can be beneficial, particularly at higher doses. However, for broader clinical applications and more significant improvements in vitamin D status, cholecalciferol appears to be the superior choice. Further research is needed to explore the long-term clinical outcomes of ergocalciferol supplementation in various patient groups.
Sources and full results
Most relevant research papers on this topic